{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T03:21:21Z","timestamp":1779938481016,"version":"3.53.1"},"reference-count":23,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Human Gene Therapy"],"published-print":{"date-parts":[[2016,12]]},"abstract":"\n Detection of exogenous\n p53<\/jats:italic>\n gene and target gene expression in cervical cancer cell lines SiHa and C33A infected by recombinant adenovirus-\n p53<\/jats:italic>\n (rAd-\n p53<\/jats:italic>\n )\n in vitro<\/jats:italic>\n . The rAd-\n p53<\/jats:italic>\n infection evidently increased the expression of exogenous\n p53<\/jats:italic>\n gene,\n p21<\/jats:italic>\n gene, and\n Bax<\/jats:italic>\n gene. The radiosensitization rates of rAd-\n p53<\/jats:italic>\n were 1.19 in SiHa and 1.18 in C33A\n in vitro<\/jats:italic>\n . To evaluate the effect and safety of rAd-\n p53<\/jats:italic>\n transfer combined with radiotherapy (RT) in patients with cervical cancer, rAd-\n p53<\/jats:italic>\n transfer combined with radiotherapy (group PRT) in 69 patients with cervical cancer was compared with a control group treated with radiotherapy alone (group RT) in 35 patients with cervical cancer. Patients were intratumorally injected with rAd-\n p53<\/jats:italic>\n (1\u2009\u00d7\u200910\n 12<\/jats:sup>\n virus particles) once a week for 6 weeks. Concurrent pelvic RT plus brachytherapy to take point A to 76.0 Gray units (Gy) (range 75\u201380 Gy). The 5-year overall survival rate of the PRT group was 17.5% higher than that of the RT group (HR\u2009=\u20090.551, 95% CI 0.278\u20131.095,\n p<\/jats:italic>\n \u2009=\u20090.084). The 5-year progress-free survival rate of the PRT group was 17.1% higher than that of the RT group (HR\u2009=\u20090.485, 95% CI 0.234\u20131.006,\n p<\/jats:italic>\n \u2009=\u20090.047). rAd-\n p53<\/jats:italic>\n administration did not increase the adverse events caused by radiotherapy, except for transient fever after rAd-\n p53<\/jats:italic>\n administration. rAd-\n p53<\/jats:italic>\n was safe and biologically active in improving radiotherapeutic survival rates in patients with cervical cancer.\n <\/jats:p>","DOI":"10.1089\/hum.2016.043","type":"journal-article","created":{"date-parts":[[2016,8,30]],"date-time":"2016-08-30T10:47:44Z","timestamp":1472554064000},"page":"1008-1014","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":33,"title":["Effect and Safety of Recombinant Adenovirus-\n p53<\/i>\n Transfer Combined with Radiotherapy on Long-Term Survival of Locally Advanced Cervical Cancer"],"prefix":"10.1177","volume":"27","author":[{"given":"Xing","family":"Su","sequence":"first","affiliation":[{"name":"Peking University Cancer Hospital and Institute","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-juan","family":"Chen","sequence":"additional","affiliation":[{"name":"Fujian Province Cancer Hospital","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-wen","family":"Xiao","sequence":"additional","affiliation":[{"name":"Peking University Cancer Hospital and Institute","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-fan","family":"Li","sequence":"additional","affiliation":[{"name":"Peking University Cancer Hospital and Institute","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Xu","sequence":"additional","affiliation":[{"name":"Peking University Cancer Hospital and Institute","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-ji","family":"Pan","sequence":"additional","affiliation":[{"name":"Fujian Province Cancer Hospital","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-wen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking University Cancer Hospital and Institute","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,12,1]]},"reference":[{"key":"e_1_3_3_2_2","first-page":"116","article-title":"Effects of tumor suppress gene p53 on radiosensitivity for human gastric carcinoma cell lines","volume":"2","author":"Zhang SW","year":"1999","unstructured":"Zhang SW, , Xiao WQ, , Lu YY. Effects of tumor suppress gene p53 on radiosensitivity for human gastric carcinoma cell lines. Chin J Radio-oncol, 1999; 2:116\u2013119.","journal-title":"Chin J Radio-oncol"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11670-003-0004-4"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.9670"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S50483"},{"key":"e_1_3_3_6_2","first-page":"3617","article-title":"Update knowledge on cervical cancer incidence and prevalence in Asia","volume":"9","author":"Daniyal M","year":"2010","unstructured":"Daniyal M, , Akhtar N, , Ahmad S, et al. Update knowledge on cervical cancer incidence and prevalence in Asia. Asian Pac J Cancer Prev, 2010; 9:3617\u201320.","journal-title":"Asian Pac J Cancer Prev"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2886"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12250-015-3586-3"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.2186"},{"key":"e_1_3_3_10_2","first-page":"70","article-title":"Expression of HPV-16 E6 Protein and p53 Inactivation Increases the Uterine Cervical Cancer Invasion","volume":"2","author":"Yang X.","year":"2015","unstructured":"Yang X., , Lu L. Expression of HPV-16 E6 Protein and p53 Inactivation Increases the Uterine Cervical Cancer Invasion. Drug Res, 2015; 2:70\u201373.","journal-title":"Drug Res"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-013-9674-5"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2002.6838"},{"key":"e_1_3_3_13_2","first-page":"865","article-title":"Tumor hyposia, p53, and prognosis in cervical cancers","volume":"4","author":"Haensgen G","year":"2002","unstructured":"Haensgen G, , Krause U, , Becker A, et al. Tumor hyposia, p53, and prognosis in cervical cancers. Int J Radiat Oncol Biol Phys, 2002; 4:865\u2013872.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1983"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2013.02.034"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2008.03.001"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2006.09.007"},{"key":"e_1_3_3_18_2","first-page":"CD001774","article-title":"Neoadjuvant chemotherapy for locally advanced cervix cancer","volume":"2","author":"Neoadjuvant Chemotherapy for Cervical Cancer Meta-Analysis (NACCCMA) Collaboration","year":"2004","unstructured":"Neoadjuvant Chemotherapy for Cervical Cancer Meta-Analysis (NACCCMA) Collaboration. Neoadjuvant chemotherapy for locally advanced cervix cancer. Cochrane Database Syst Rev, 2004; 2:CD001774.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_19_2","first-page":"467","article-title":"Efficiency and side effects of concurrent radiotherapy and chemotherapy for advanced cervical cancers","volume":"6","author":"Bai P","year":"2007","unstructured":"Bai P, , Zhang R, , Li XG, et al. Efficiency and side effects of concurrent radiotherapy and chemotherapy for advanced cervical cancers. Chin J Tumor, 2007; 6:467\u2013469.","journal-title":"Chin J Tumor"},{"key":"e_1_3_3_20_2","first-page":"349","article-title":"Concurrent chemoradiation versus radiotherapy alone in cervical carcinoma: A randomized phase III trial","volume":"4","author":"Kirti S","year":"2013","unstructured":"Kirti S, , Sayan P, , Kundan SC, et al. Concurrent chemoradiation versus radiotherapy alone in cervical carcinoma: A randomized phase III trial. Asia Pac J Clin Oncol, 2013; 4:349\u2013356.","journal-title":"Asia Pac J Clin Oncol"},{"key":"e_1_3_3_21_2","unstructured":"Ying WB Gu XZ. Tumor Radiotherapy. Beijing: Chinese XieHe Medical University Publishing Company 2002:920."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2003.10.033"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-8258(03)00054-4"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2006.38.3.168"}],"container-title":["Human Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/hum.2016.043","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2016.043","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2016.043","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T07:02:19Z","timestamp":1779692539000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/hum.2016.043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1089\/hum.2016.043"],"URL":"https:\/\/doi.org\/10.1089\/hum.2016.043","relation":{},"ISSN":["1043-0342","1557-7422"],"issn-type":[{"value":"1043-0342","type":"print"},{"value":"1557-7422","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}